Immunotherapy for endometrial cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Immune checkpoint inhibitors (ICIs) show promise for advanced endometrial cancer (EC). Pembrolizumab combined with lenvatinib improves outcomes for recurrent EC, regardless of microsatellite instability (MSI) status.
Area Of Science
- Oncology
- Genomics
- Immunotherapy
Background
- Advanced recurrent endometrial cancer (EC) presents a significant clinical challenge with limited treatment options.
- Genomic classification of EC into four subtypes (POLE, MSI-H, copy number low, copy number high) impacts prognosis and treatment strategies.
- Endometrial cancer exhibits high PD-1 and PD-L1 expression, particularly in the MSI-high subtype, suggesting sensitivity to immune checkpoint inhibitors (ICIs).
Purpose Of The Study
- To review the evolving role of ICIs in the treatment of advanced recurrent endometrial cancer.
- To highlight the efficacy of pembrolizumab, alone and in combination, for EC treatment.
- To discuss the management of immune-related adverse events (irAEs) associated with ICI therapy.
Main Methods
- Review of clinical trial data and literature on ICI therapy in recurrent endometrial cancer.
- Analysis of genomic classifications and their correlation with PD-L1 expression and treatment response.
- Evaluation of combination therapies involving ICIs, chemotherapy, and targeted agents like lenvatinib.
Main Results
- Pembrolizumab demonstrated efficacy in MSI-high recurrent EC.
- The combination of pembrolizumab and lenvatinib significantly improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in previously treated recurrent EC, irrespective of MSI status.
- ICI-based regimens are increasingly used in first-line settings, with ongoing trials comparing them to traditional chemotherapy.
Conclusions
- ICIs, particularly pembrolizumab in combination with lenvatinib, represent a significant advancement in treating advanced recurrent endometrial cancer.
- Treatment individualization based on genomic classification, especially MSI status, is crucial.
- While effective, ICIs can cause immune-related adverse events (irAEs), necessitating prompt management, especially with combination therapies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...